Aug 21, 2025 • Zacks Commentary
NEUTRAL
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
Aug 21, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global ...
Aug 21, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, ICELAND and LONDON, UK ( August 21, 2025 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global ...
Aug 20, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
REYKJAVIK, ICELAND ( August 20, 2025 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in ...
Aug 14, 2025 • Zacks Commentary
NEUTRAL
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Aug 13, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Alvotech ( ALVO ) Q2 Earnings and Revenues Beat Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of +153.85% and +50.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?